A phase II, single‐arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B‐cell lymphoma

Overview of attention for article published in British Journal of Haematology, March 2016

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (91st percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news: 1 news outlet
twitter: 1 X user

patent: 5 patents

Readers on

mendeley: 52 Mendeley

So far, Altmetric has seen 5 patents that reference this research output.

Dosage regimes for the administration of an anti-CD19 ADC

Grant US-11938192-B2

United States of America

26 Mar 2024

Dosage regimes for the administration of an anti-CD19 ADC

Grant US-11318211-B2

United States of America

03 May 2022

Combination therapy

Application JP-2020517640-A

Japan

18 Jun 2020

Combination therapy

Application CN-110869765-A

China

06 Mar 2020

This page shows the most recent patents that mention this research output. Click here to find out how to access more activity, including 1 additional patents.